On August 23, 2022, Viracta Therapeutics, Inc. announced Michael Huang notified the Company of his resignation as a member of the Board of Directors of the Company and from all committees of the Board on which he served, effective as of August 23, 2022. Mr. Huang's resignation is not the result of any disagreement with the Company relating to the Company's operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 USD | +1.43% | -4.76% | +22.81% |
05-30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
05-23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 27.1M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director